1899. Deputy Ken O'Flynn asked the Minister for Health whether any national framework exists to measure consistency of service eligibility decisions across Health Regions; and if she will make a statement on the matter. [41866/26]
1900. Deputy Ken O'Flynn asked the Minister for Health whether any patient-impact analysis has been conducted regarding regional variation in decision-making within the Health Regions structure; and if she will make a statement on the matter. [41867/26]
1901. Deputy Ken O'Flynn asked the Minister for Health whether compliance with agency staffing restrictions forms part of any current HSE risk register, assurance framework, or governance monitoring process; and if she will provide details. [41868/26]
1902. Deputy Ken O'Flynn asked the Minister for Health whether any analysis has been conducted into the operational or patient safety impact of agency staffing restrictions introduced in July 2025; and if she will provide details. [41869/26]
1903. Deputy Ken O'Flynn asked the Minister for Health to identify the specific unit, division or named office within her Department responsible for governance oversight of the treatment abroad scheme. [41870/26]
1904. Deputy Ken O'Flynn asked the Minister for Health whether the treatment abroad scheme is subject to a documented risk-management framework; and if so, whether she will provide the title and date of the current framework. [41871/26]
1905. Deputy Ken O'Flynn asked the Minister for Health the dates on which the treatment abroad scheme was audited by HSE Internal Audit since 2020; and whether any recommendations were issued following those audits. [41872/26]
1906. Deputy Ken O'Flynn asked the Minister for Health the dates on which the Comptroller and Auditor General conducted any audit, review or examination relating to the treatment abroad scheme since 2020. [41873/26]
1907. Deputy Ken O'Flynn asked the Minister for Health whether any expenditure-control thresholds, referral-value triggers or enhanced approval mechanisms apply within the treatment abroad scheme for high-cost treatments. [41874/26]
1908. Deputy Ken O'Flynn asked the Minister for Health whether her Department receives regular reporting regarding the number and aggregate value of treatment abroad scheme approvals by specialty or treatment category. [41875/26]
1909. Deputy Ken O'Flynn asked the Minister for Health whether any formal value-for-money review of the treatment abroad scheme has been conducted since 2020; and if so, when and by whom. [41876/26]
1910. Deputy Ken O'Flynn asked the Minister for Health whether the treatment abroad scheme appears on any Department of Health or HSE corporate or operational risk register. [41877/26]
1913. Deputy Ken O'Flynn asked the Minister for Health whether the treatment abroad scheme maintains a unique case identifier linking each approved application to associated invoices, reimbursement records, payment dates, and treatment completion records; and if she will make a statement on the matter. [41882/26]
1914. Deputy Ken O'Flynn asked the Minister for Health whether all expenditure under the treatment abroad scheme is capable of being reconciled on a patient-by-patient basis through a single integrated dataset; and if she will make a statement on the matter. [41883/26]
1915. Deputy Ken O'Flynn asked the Minister for Health whether the treatment abroad scheme operates through a fully integrated digital financial management and verification system or through manual and partially manual reconciliation processes; and if she will make a statement on the matter. [41884/26]
1916. Deputy Ken O'Flynn asked the Minister for Health whether payments made under the treatment abroad scheme are subject to post-treatment verification procedures prior to final reimbursement; and if she will provide details of the verification process applied. [41885/26]
1917. Deputy Ken O'Flynn asked the Minister for Health whether any overpayments, duplicate payments, unverified invoices, disputed charges, or retrospective expenditure adjustments have been identified within the treatment abroad scheme since 2020; and if she will provide annual figures in tabular form. [41886/26]
1918. Deputy Ken O'Flynn asked the Minister for Health the date on which the most recent internal audit review of the treatment abroad scheme was completed; whether any recommendations were issued arising from that review; and if she will make a statement on the matter. [41887/26]
1919. Deputy Ken O'Flynn asked the Minister for Health whether the Comptroller and Auditor General has conducted any audits, examinations, management letter observations, or recommendations relating to the treatment abroad scheme since 2020; and if she will make a statement on the matter. [41888/26]
1920. Deputy Ken O'Flynn asked the Minister for Health whether the Department of Health receives patient-level expenditure and activity reports relating to the treatment abroad scheme or solely aggregate expenditure and activity summaries; and if she will make a statement on the matter. [41889/26]
1921. Deputy Ken O'Flynn asked the Minister for Health whether any formal risk assessment has been conducted regarding financial accountability, expenditure verification, invoice reconciliation, or audit assurance arrangements within the treatment abroad scheme since 2020; and if she will provide details. [41890/26]
1922. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has conducted any review, assessment, or procurement exercise regarding the development of a comprehensive patient-linked financial accountability system for the treatment abroad scheme; and if she will make a statement on the matter. [41891/26]
1923. Deputy Ken O'Flynn asked the Minister for Health whether there exists any statutory, administrative, or policy requirement setting minimum audit frequency standards for the treatment abroad scheme; and if she will make a statement on the matter. [41892/26]
1924. Deputy Ken O'Flynn asked the Minister for Health whether quarterly oversight meetings between the HSE and the Department of Health concerning the treatment abroad scheme include review of patient-level expenditure verification, invoice reconciliation, or audit exception reporting; and if she will make a statement on the matter. [41893/26]
1926. Deputy Ken O'Flynn asked the Minister for Health whether the treatment abroad scheme maintains a formal panel of independent clinical reviewers to assess applications prior to approval of expenditure; if so, the composition and governance arrangements of that panel; and if she will make a statement on the matter. [41905/26]